Core operating income margin was 34.3% of net sales, increasing by 1.1 percentage points (+1.0 percentage point cc).Ĭore net income was USD 3.8 billion (+10%, +9% cc). EPS was USD 1.23 (+45%, +44% cc), growing faster than net income benefiting from lower weighted average number of shares outstanding.Ĭore operating income was USD 4.5 billion (+10%, +9% cc) benefiting from higher sales and productivity programs, partly offset by higher investments in M&S and R&D. Net income was USD 2.8 billion (+43%, +41% cc). Operating income was USD 3.2 billion (+34%, +32% cc) predominately from higher sales and lower impairment charges, partly offset by higher investments in M&S and R&D. Volume growth was partly offset by price erosion of 2 percentage points and generic competition of 2 percentage points. Volume contributed 9 percentage points to sales growth, driven by Entresto, Cosentyx, Kesimpta and Jakavi. Net sales were USD 13.0 billion (+6%, +5% cc) in the third quarter. Its global portfolio covers all major therapeutic areas with a global market leadership position in biosimilars, generic antibiotics and oncology medicines. Sandoz is a global leader in generic pharmaceuticals and biosimilars.
The review will explore all options, ranging from retaining the business to separation, in order to determine how to best maximize value for our shareholders.
Novartis has commenced a strategic review of the Sandoz Division. We remain confident in the strength of our pipeline and launch brands to fuel the growth of our company in the mid to longer term.” We are also commencing a strategic review of Sandoz to maximize shareholder value. Rejuvenation of our portfolio continues, from our key brands which include Kesimpta, Leqvio, Zolgensma and the oncology portfolio. “Novartis delivered strong Innovative Medicines performance, driven by the continued momentum of Cosentyx and Entresto, allowing us to raise peak sales guidance for these products. Remibrutinib met primary endpoint in Ph2b CSU study Ph3 in CSU and MS plannedġ77 Lu-PSMA-617 and Asciminib granted priority review by FDAĬommencing a strategic review of Sandoz to maximize shareholder value, options range from retaining the business to separationīasel, Octocommenting on the quarter, Vas Narasimhan, CEO of Novartis, said: Kisqali demonstrated statistically significant OS benefit for 1L HR+/HER2- advanced breast cancerĬosentyx met primary endpoint in Ph2 Giant Cell Arteritis study Ph3 started
Zolgensma partial clinical trial hold lifted by FDA Ph3 IT clinical trial for SMA to proceed Q4 2021 Increasing peak sales guidance for Cosentyx (at least USD 7.0 billion) and Entresto (at least USD 5.0 billion) Sandoz sales declined -4% (cc, 0% USD) and core operating income declined -18% (cc, -15% USD) Innovative Medicines sales grew +6% (cc, +9% USD) and core operating income +8% (cc, +11% USD) Nine months sales grew +4% (cc, +7% USD) and core operating income grew +4% (cc, +7% USD)
Q3 free cash flow 1 of USD 4.4 billion (+64% USD), with higher operating income, lower payments out of provisions and favorable changes in working capital Q3 net income increased +41% (cc, +43% USD)
Q3 operating income grew +32% (cc, +34% USD)
Sandoz declined -15% (cc, -13% USD), impacted by gross margin Innovative Medicines grew +13% (cc, +14% USD), due to higher sales and productivity programs Q3 core¹ operating income grew +9% (cc, +10% USD) Sandoz declined -2% (cc, -1% USD), affected by continued pricing pressures. Strong performance of key growth drivers: Entresto (+44% cc), Cosentyx (+22% cc), Kesimpta (USD 109 million), Jakavi (+26% cc), Zolgensma (+28% cc), Promacta/Revolade (+18% cc) and Kisqali (+27% cc) Innovative Medicines grew +7% (cc, +8% USD)